The half-maximal inhibitory concentration (IC₅₀) is a key pharmacological parameter for quantifying drug efficacy. We developed a label-free, contrast-enhanced surface plasmon resonance imaging technique to assess drug-induced cytotoxicity in cells. Compared to conventional assays such as cell proliferation kits and viability fluorescent staining, our platform yields highly consistent results. It enables accurate IC₅₀ measurement with the advantages of high throughput and label-free detection.

We developed a new platform that combines patented nanoplasmonic chips with contrast-enhanced imaging technology, achieving a label-free, highly sensitive, low-cost, and commercially viable detection system. This platform employs mass-produced nanostructures and a simple imaging setup, has been granted patents in multiple countries, and demonstrates practical applications in high-throughput cellular activity measurement.

A novel surface plasmon resonance sensing platform integrating patented nanoplasmonic chips with contrast-enhanced imaging technology offers label-free detection with high sensitivity and low cost. This technology is broadly applicable in the biomedical field, providing high-throughput and accurate evaluation of drug efficacy with strong market potential. The platform is also well-suited for applications such as molecular interaction analysis, pollutant monitoring, and food safety testing.